Novartis's Kymriah Comes Up Short In NHL Study
Rivals Yescarta And Breyanzi Have Succeeded In Similar Trials
The BELINDA study investigating Kymriah as second-line treatment in aggressive B-cell non-Hodgkin lymphoma has missed its primary endpoint, thwarting Novartis's hopes of getting the CAR-T therapy into earlier-stage use.
